Enrolling
Longitudinal impacts of violence and stigma on HIV care continuum and broader health care access among women living with HIV
Learn MoreEnrolling
The role of fatty liver in the epidemic of advanced chronic liver disease among people living with HIV
Learn MoreOngoing
Drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV
Learn MoreOngoing
Optimising Outcomes at Critical Points in the Cascade of HIV Care in Ontario
Learn MoreReporting
Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)
Learn MoreOngoing
The impact of COVID-19 on persons with HIV in Canada: Data from the HIV/HCV co-infection/CCC (CTN 222) and HIV aging cohorts (CTN 314)
Learn MoreReporting
Electronic capture through the Opal patient portal of a patient-reported measure of barriers to antiretroviral therapy adherence: a mixed method type 3 hybrid pilot study at a large Montreal HIV clinic
Learn MoreCompleted
Transgender women removing healthcare barriers to engagement in the HIV prevention and care cascades
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
